SAGE Therapeutics Inc (SAGE) : New Leaf Venture Partners L.l.c. added new position in SAGE Therapeutics Inc during the most recent quarter end. The investment management firm now holds 142,570 shares of SAGE Therapeutics Inc which is valued at $5,233,745 , the company said in a statement filed on Aug 15, 2016 with the SEC.SAGE Therapeutics Inc makes up approximately 4.27% of New Leaf Venture Partners L.l.c.’s portfolio.
Other Hedge Funds, Including , Putnam Investments reduced its stake in SAGE by selling 124 shares or 0.63% in the most recent quarter. The Hedge Fund company now holds 19,430 shares of SAGE which is valued at $713,275.Blackrock Fund Advisors boosted its stake in SAGE in the latest quarter, The investment management firm added 250,382 additional shares and now holds a total of 1,037,928 shares of SAGE Therapeutics Inc which is valued at $38,102,337. SAGE Therapeutics Inc makes up approx 0.01% of Blackrock Fund Advisors’s portfolio.Teacher Retirement System Of Texas boosted its stake in SAGE in the latest quarter, The investment management firm added 973 additional shares and now holds a total of 3,522 shares of SAGE Therapeutics Inc which is valued at $149,544.California Public Employees Retirement System reduced its stake in SAGE by selling 300 shares or 3.19% in the most recent quarter. The Hedge Fund company now holds 9,100 shares of SAGE which is valued at $400,491.Harvey Capital Management Inc reduced its stake in SAGE by selling 1,360 shares or 8.04% in the most recent quarter. The Hedge Fund company now holds 15,545 shares of SAGE which is valued at $689,887. SAGE Therapeutics Inc makes up approx 0.33% of Harvey Capital Management Inc’s portfolio.
SAGE Therapeutics Inc closed down -0.21 points or -0.56% at $36.96 with 2,39,650 shares getting traded on Thursday. Post opening the session at $37.33, the shares hit an intraday low of $36.23 and an intraday high of $37.65 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
Many Wall Street Analysts have commented on SAGE Therapeutics Inc. H.C. Wainwright Initiated SAGE Therapeutics Inc on Jun 23, 2016 to “Buy”, Price Target of the shares are set at $56.Chardan Capital Markets Initiated SAGE Therapeutics Inc on May 24, 2016 to “Sell”, Price Target of the shares are set at $18.
SAGE Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat life-threatening rare central nervous system (CNS) disorders. The Company’s lead product candidate in its status epilepticus (SE) program is SAGE-547. SAGE-689 and SAGE-217 are two additional product candidates in its pipeline. The Company has submitted investigational new drug (IND) for SAGE-547 for the treatment of SRSE with the United States Food and Drug Administration. SAGE-547 is an allosteric modulator of both synaptic and extra-synaptic GABAA receptors. SAGE-217 is a neuroactive steroid that acts as a positive allosteric modulator of synaptic and extra-synaptic GABAA receptor subtypes. SAGE-689 is being developed as an adjunctive IV therapy for the treatment of status epilepticus patients.